Follicular lymphoma
Conditions
Sponsors
Suzuki Kenta
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically diagnosed as Grade 1, 2 or 3a FL according to WHO classification 2) Relapsed or refractory disease after receiving at least two prior systemic therapies 3) At least one measurable lesion according to the Lugano classification 4) ECOG PS of 0 to 1 5) Written informed consent
Exclusion criteria
Exclusion criteria: 1) Clinically or histologically suspected to be transformation from FL to an aggressive lymphoma or diagnosed as Grade 3b FL according to WHO classification 2) History of interstitial pneumonia or severe lung dysfunction 3) Received prior treatment with duvelisib (Patients who were refractory to PI3K inhibitors other than duvelisib or who experienced severe adverse events during treatment with the PI3K inhibitor were also excluded.) 4) Ongoing treatment for systemic bacterial, fungal, or viral infection 5) Administration of medications or foods that are strong inhibitors or inducers of CYP3A within 14 days of enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate | — |
Contacts
Public ContactDevelopment Clinical
Yakult Honsha Co., Ltd.
Outcome results
None listed